Session Information
Session Type: Abstract Submissions (ACR)
Background/Purpose Using data from GO-RAISE, we analyzed correlations between serum vascular endothelial growth factor (VEGF) and C-reactive protein (CRP) levels, radiographic progression and inflammation as detected by MRI.
Methods 98 patients with active AS received golimumab or placebo up to wk16/24 and then golimumab up to 2y. All had sera, lateral spinal radiographs at baseline, wk104, and wk208 scored by the mSASSS and spinal MRIs at baseline, wk14, and wk104 scored with the ASspiMRI‑a by two blinded readers. The relationship between VEGF or CRP levels and both mSASSS and MRI-a score was assessed by Spearman correlation analyses and logistic regression analyses were conducted to assess if VEGF levels conferred an increased risk of syndesmophyte formation from baseline to wk104 or wk208.
Results CRP serum levels correlated with mSASSS scores at baseline, but not with radiographic progression or changes in MRI-a scores. No significant correlations were observed between VEGF serum levels and mSASSS at any time point. Logistic regression analyses failed to show an increased risk of changes towards syndesmophyte formation at wk104 and wk208 associated with VEGF (odds ratio, range: 0.990-1.006, all p=n.s). While a good correlation was observed between changes in ASspiMRI-a and VEGF level at wk14 (p=0.0008), the analysis showed that baseline and wk14 VEGF levels were not predictive of MRI-a scores including change scores at wk104
Conclusion CRP serum levels correlated with baseline mSASSS scores but did not predict radiographic progression or remaining spinal inflammation after anti-TNF treatment. Similarly, both VEGF and CRP serum levels at baseline were not predictive of either radiographic progression or spinal inflammation in these anti-TNF treated patients. Overall, our data suggest that suppression of VEGF and CRP is not sufficient to halt new bone formation in AS.
Disclosure:
X. Baraliakos,
Janssen R and D, LLC,
2;
K. G. A. Hermann,
Janssen R and D, LLC,
2;
S. Xu,
Janssen Research & Development, LLC.,
3;
B. Hsu,
Janssen Research & Development, LLC.,
3;
J. Braun,
Abbott, Bristol Myers Squibb, Celgene, Celltrion, Chugai, Johnson & Johnson, MSD, Novartis, Pfizer, Roche, UCB Pharma,
5,
Abbott, Bristol Myers Squibb, Celgene, Celltrion, Chugai, Johnson & Johnson, MSD, Novartis, Pfizer, Roche, UCB Pharma,
2.
« Back to 2014 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/vascular-endothelial-growth-factor-and-c-reactive-protein-serum-levels-lack-predictive-value-for-radiographic-and-magnetic-resonance-imaging-outcomes-in-patients-with-active-ankylosing-spondyliti/